ReviewFrontiers in molecular biosciences2026
C/EBPα plays a critical role in adipocyte differentiation and obesity.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sulforaphane and Broccoli-Derived Preparations in Obesity and Obesity-Related Metabolic Dysfunction: Mechanistic Insights, Preclinical Evidence, and Clinical Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CCAAT/enhancer-binding protein alpha (C/EBPα), a key member of the transcription factor family, inhibits proliferation and plays a central role in adipocyte differentiation, hematopoiesis, and other cellular processes. Its expression and activity are finely regulated at multiple levels, including transcriptional, post-transcriptional, translational, and post-translational modifications. During adipocyte differentiation, C/EBPα participates in establishing a complex regulatory network by coordinating with other transcription factors and modulating downstream key genes such as peroxisome proliferator-activated receptor γ (PPARγ). In obesity, dysregulation of C/EBPα is closely associated with impaired adipocyte differentiation and abnormal lipid metabolism, often contributing to lipid accumulation and hyperlipidemia. As research advances, therapeutic strategies targeting C/EBPα have opened new avenues for obesity intervention. However, numerous challenges remain in translating basic research into clinical applications. This review aims to elucidate the mechanisms and research advances regarding the role of C/EBPα in adipocyte differentiation and obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.